Bastard JP, Maachi M, Lagathu C, et al: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 17:4–12. 2006.PubMed/NCBI

Cnop M, Havel PJ, Utzschneider KM, et al: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 46:459–469. 2003.PubMed/NCBI

Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. Nature. 405:421–424. 2000. View Article : Google Scholar : PubMed/NCBI

Lakka HM, Laaksonen DE, Lakka TA, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 288:2709–2716. 2002. View Article : Google Scholar : PubMed/NCBI

Sattar N, Gaw A, Scherbakova O, et al: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 108:414–419. 2003. View Article : Google Scholar

Grundy SM, Brewer HB Jr, Cleeman JI, et al: Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 24:e13–e18. 2004. View Article : Google Scholar

Greenberg AS and Obin MS: Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 83:461S–465S. 2006.PubMed/NCBI

Hotamisligil GS, Shargill NS and Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259:87–91. 1993. View Article : Google Scholar : PubMed/NCBI

Orio F Jr, Palomba S, Cascella T, Savastano S, Lombardi G and Colao A: Cardiovascular complications of obesity in adolescents. J Endocrinol Invest. 30:70–80. 2007. View Article : Google Scholar

Grundy SM: Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 89:2595–2600. 2004. View Article : Google Scholar : PubMed/NCBI

Shoelson SE and Goldfine AB: Getting away from glucose: fanning the flames of obesity-induced inflammation. Nat Med. 15:373–374. 2009. View Article : Google Scholar : PubMed/NCBI

Leone TC, Weinheimer CJ and Kelly DP: A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA. 96:7473–7478. 1999. View Article : Google Scholar

Iizuka K and Horikawa Y: ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr J. 55:617–624. 2008. View Article : Google Scholar : PubMed/NCBI

Berger J and Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 53:409–435. 2002. View Article : Google Scholar : PubMed/NCBI

Viana Abranches M, Esteves de Oliveira FC and Bressan J: Peroxisome proliferator-activated receptor: effects on nutritional homeostasis, obesity and diabetes mellitus. Nutr Hosp. 26:271–279. 2011.

Adeghate E, Adem A, Hasan MY, Tekes K and Kalasz H: Medicinal chemistry and actions of dual and pan PPAR modulators. Open Med Chem J. 5:93–98. 2011. View Article : Google Scholar : PubMed/NCBI

Israelian-Konaraki Z and Reaven PD: Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology. 103:1–9. 2005. View Article : Google Scholar

Nicholls SJ and Uno K: Peroxisome proliferator-activated receptor (PPAR alpha/gamma) agonists as a potential target to reduce cardiovascular risk in diabetes. Diab Vasc Dis Res. 9:89–94. 2012. View Article : Google Scholar

Salmenniemi U, Ruotsalainen E, Pihlajamäki J, et al: Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 110:3842–3848. 2004. View Article : Google Scholar

Mujica V, Leiva E, Icaza G, et al: Evaluation of metabolic syndrome in adults of Talca city, Chile. Nutr J. 7:142008. View Article : Google Scholar : PubMed/NCBI

Palomo I, Contreras A, Alarcon LM, et al: Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. Nitric Oxide. 24:224–228. 2011. View Article : Google Scholar : PubMed/NCBI

Palomo I, Moore-Carrasco R, Alarcon M, et al: Pathophysiology of the proatherothrombotic state in the metabolic syndrome. Front Biosci (Schol Ed). 2:194–208. 2010. View Article : Google Scholar : PubMed/NCBI

Palomo I, Alarcón M, Moore-Carrasco R and Argilés JM: Hemostasis alterations in metabolic syndrome (review). Int J Mol Med. 18:969–974. 2006.PubMed/NCBI

Salmenniemi U, Ruotsalainen E, Vänttinen M, et al: High amount of visceral fat mass is associated with multiple metabolic changes in offspring of type 2 diabetic patients. Int J Obes (Lond). 29:1464–1470. 2005. View Article : Google Scholar : PubMed/NCBI

Flier JS: Obesity wars: molecular progress confronts an expanding epidemic. Cell. 116:337–350. 2004. View Article : Google Scholar : PubMed/NCBI

Ahima RS: Adipose tissue as an endocrine organ. Obesity (Silver Spring). 14:242S–249S. 2006. View Article : Google Scholar

Barreda R and Ros PR: Diagnostic imaging of liver abscess. Crit Rev Diagn Imaging. 33:29–58. 1992.PubMed/NCBI

Pittas AG, Joseph NA and Greenberg AS: Adipocytokines and insulin resistance. J Clin Endocrinol Metab. 89:447–452. 2004. View Article : Google Scholar : PubMed/NCBI

Satoh M, Andoh Y, Clingan CS, et al: Type II NKT cells stimulate diet-induced obesity by mediating adipose tissue inflammation, steatohepatitis and insulin resistance. PLoS One. 7:e305682012. View Article : Google Scholar : PubMed/NCBI

Lumeng CN and Saltiel AR: Inflammatory links between obesity and metabolic disease. J Clin Invest. 121:2111–2117. 2011. View Article : Google Scholar : PubMed/NCBI

Xu H, Barnes GT, Yang Q, et al: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 112:1821–1830. 2003. View Article : Google Scholar : PubMed/NCBI

Kern PA, Ranganathan S, Li C, Wood L and Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 280:E745–751. 2001.PubMed/NCBI

Shimomura I, Funahashi T, Takahashi M, et al: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 2:800–803. 1996. View Article : Google Scholar : PubMed/NCBI

Bruce CR and Dyck DJ: Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab. 287:E616–E621. 2004. View Article : Google Scholar : PubMed/NCBI

Dyck DJ: Adipokines as regulators of muscle metabolism and insulin sensitivity. Appl Physiol Nutr Metab. 34:396–402. 2009.PubMed/NCBI

Kriketos AD, Greenfield JR, Peake PW, et al: Inflammation, insulin resistance, and adiposity: a study of first-degree relatives of type 2 diabetic subjects. Diabetes Care. 27:2033–2040. 2004. View Article : Google Scholar : PubMed/NCBI

Kaidashev IP: NF-kB activation as a molecular basis of pathological process by metabolic syndrome. Fiziol Zh. 58:93–101. 2012.(In Ukranian).

Ahn J, Lee H, Kim S and Ha T: Resveratrol inhibits TNF-alpha-induced changes of adipokines in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 364:972–977. 2007. View Article : Google Scholar : PubMed/NCBI

Hotamisligil GS, Arner P, Caro JF, Atkinson RL and Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 95:2409–2415. 1995. View Article : Google Scholar : PubMed/NCBI

Araki K, Kawauchi K and Tanaka N: IKK/NF-kappaB signaling pathway inhibits cell-cycle progression by a novel Rb-independent suppression system for E2F transcription factors. Oncogene. 27:5696–5705. 2008. View Article : Google Scholar : PubMed/NCBI

Gupta S and Gupta BM: Metabolic syndrome: diabetes and cardiovascular disease. Indian Heart J. 58:149–152. 2006.PubMed/NCBI

Mujica V, Urzua A, Leiva E, et al: Intervention with education and exercise reverses the metabolic syndrome in adults. J Am Soc Hypertens. 4:148–153. 2010. View Article : Google Scholar : PubMed/NCBI

Klimcakova E, Roussel B, Kovacova Z, et al: Macrophage gene expression is related to obesity and the metabolic syndrome in human subcutaneous fat as well as in visceral fat. Diabetologia. 54:876–887. 2011. View Article : Google Scholar : PubMed/NCBI

Kallio P, Kolehmainen M, Laaksonen DE, et al: Dietary carbohydrate modification induces alterations in gene expression in abdominal subcutaneous adipose tissue in persons with the metabolic syndrome: the FUNGENUT Study. Am J Clin Nutr. 85:1417–1427. 2007.

Vernochet C, Peres SB, Davis KE, et al: C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol Cell Biol. 29:4714–4728. 2009. View Article : Google Scholar

Xue B, Sukumaran S, Nie J, Jusko WJ, Dubois DC and Almon RR: Adipose tissue deficiency and chronic inflammation in diabetic Goto-Kakizaki rats. PLoS One. 6:e173862011. View Article : Google Scholar : PubMed/NCBI

Wahli W, Braissant O and Desvergne B: Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol. 2:261–266. 1995. View Article : Google Scholar : PubMed/NCBI

Motojima K: Peroxisome proliferator-activated receptor (PPAR): structure, mechanisms of activation and diverse functions. Cell Struct Funct. 18:267–277. 1993. View Article : Google Scholar : PubMed/NCBI

Jay MA and Ren J: Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev. 3:33–39. 2007. View Article : Google Scholar : PubMed/NCBI

Keller H, Mahfoudi A, Dreyer C, et al: Peroxisome proliferator-activated receptors and lipid metabolism. Ann N Y Acad Sci. 684:157–173. 1993. View Article : Google Scholar : PubMed/NCBI

Lowell BB: PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell. 99:239–242. 1999. View Article : Google Scholar : PubMed/NCBI

Sugii S and Evans RM: Epigenetic codes of PPARgamma in metabolic disease. FEBS Lett. 585:2121–2128. 2011. View Article : Google Scholar : PubMed/NCBI

Heikkinen S, Auwerx J and Argmann CA: PPARgamma in human and mouse physiology. Biochim Biophys Acta. 1771:999–1013. 2007. View Article : Google Scholar : PubMed/NCBI

Fujiki K, Kano F, Shiota K and Murata M: Expression of the peroxisome proliferator activated receptor gamma gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes. BMC Biol. 7:382009. View Article : Google Scholar : PubMed/NCBI

Luconi M, Cantini G and Serio M: Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer? Steroids. 75:585–594. 2010. View Article : Google Scholar : PubMed/NCBI

Bouhlel MA, Derudas B, Rigamonti E, et al: PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6:137–143. 2007. View Article : Google Scholar : PubMed/NCBI

Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, et al: Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 7:496–507. 2008. View Article : Google Scholar : PubMed/NCBI

Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM and Sigmund CD: Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J Biol Chem. 285:9311–9316. 2010. View Article : Google Scholar

Halabi CM, Beyer AM, de Lange WJ, et al: Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 7:215–226. 2008. View Article : Google Scholar : PubMed/NCBI

Guri AJ, Hontecillas R, Ferrer G, et al: Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. J Nutr Biochem. 19:216–228. 2008. View Article : Google Scholar

Tsuchida A, Yamauchi T, Takekawa S, et al: Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 54:3358–3370. 2005. View Article : Google Scholar

Li Y, Cheng L, Qin Q, et al: High-fat feeding in cardiomyocyte-restricted PPARdelta knockout mice leads to cardiac overexpression of lipid metabolic genes but fails to rescue cardiac phenotypes. J Mol Cell Cardiol. 47:536–543. 2009. View Article : Google Scholar

Juge-Aubry C, Pernin A, Favez T, et al: DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. J Biol Chem. 272:25252–25259. 1997.PubMed/NCBI

Delerive P, De Bosscher K, Vanden Berghe W, Fruchart JC, Haegeman G and Staels B: DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol Endocrinol. 16:1029–1039. 2002.PubMed/NCBI

Tontonoz P and Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 77:289–312. 2008. View Article : Google Scholar : PubMed/NCBI

Cortez M, Carmo LS, Rogero MM, Borelli P and Fock RA: A high-fat diet increases IL-1, IL-6, and TNF-alpha production by increasing NF-kappaB and attenuating PPAR-gamma expression in bone marrow mesenchymal stem cells. Inflammation. 36:379–386. 2013. View Article : Google Scholar : PubMed/NCBI

Chinetti G, Fruchart JC and Staels B: Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. Int J Obes Relat Metab Disord. 27:S41–S45. 2003. View Article : Google Scholar : PubMed/NCBI

Skelhorne-Gross G and Nicol CJ: The key to unlocking the chemotherapeutic potential of PPARgamma ligands: Having the right combination. PPAR Res. 2012:9469432012. View Article : Google Scholar : PubMed/NCBI

Moore-Carrasco R, Figueras M, Ametller E, López-Soriano FJ, Argilés JM and Busquets S: Effects of the PPARgamma agonist GW1929 on muscle wasting in tumour-bearing mice. Oncol Rep. 19:253–256. 2008.PubMed/NCBI

Scheen AJ: Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf. 27:841–586. 2004. View Article : Google Scholar : PubMed/NCBI

Jiang C, Ting AT and Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:82–86. 1998. View Article : Google Scholar : PubMed/NCBI

Hong G, Davis B, Khatoon N, Baker SF and Brown J: PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation. Biochem Biophys Res Commun. 303:782–787. 2003. View Article : Google Scholar : PubMed/NCBI

Kusminski CM and Scherer PE: The road from discovery to clinic: adiponectin as a biomarker of metabolic status. Clin Pharmacol Ther. 86:592–595. 2009. View Article : Google Scholar : PubMed/NCBI

Furukawa H, Mawatari K, Koyama K, et al: Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor gamma in 3T3-L1 adipocytes. Eur J Pharmacol. 660:485–491. 2011. View Article : Google Scholar

Charbonnel B: PPAR-alpha and PPAR-gamma agonists for type 2 diabetes. Lancet. 374:96–98. 2009. View Article : Google Scholar : PubMed/NCBI

Clockaerts S, Bastiaansen-Jenniskens YM, Feijt C, et al: Cytokine production by infrapatellar fat pad can be stimulated by interleukin 1beta and inhibited by peroxisome proliferator activated receptor alpha agonist. Ann Rheum Dis. 71:1012–1018. 2012. View Article : Google Scholar : PubMed/NCBI

Delerive P, De Bosscher K, Besnard S, et al: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 274:32048–32054. 1999. View Article : Google Scholar

Guerre-Millo M, Rouault C, Poulain P, et al: PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes. 50:2809–2814. 2001. View Article : Google Scholar : PubMed/NCBI

Tordjman K, Bernal-Mizrachi C, Zemany L, et al: PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest. 107:1025–1034. 2001. View Article : Google Scholar : PubMed/NCBI

Holst JJ and McGill MA: Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants. Clin Drug Investig. 32:1–14. 2012. View Article : Google Scholar : PubMed/NCBI

Maida A, Lamont BJ, Cao X and Drucker DJ: Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia. 54:339–349. 2011. View Article : Google Scholar : PubMed/NCBI

Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J and Staels B: Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 269:31012–31018. 1994.PubMed/NCBI

Vu-Dac N, Schoonjans K, Kosykh V, et al: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 96:741–750. 1995. View Article : Google Scholar : PubMed/NCBI

Coleman JD, Prabhu KS, Thompson JT, et al: The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Free Radic Biol Med. 42:1155–1164. 2007. View Article : Google Scholar

Barish GD, Atkins AR, Downes M, et al: PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA. 105:4271–4276. 2008. View Article : Google Scholar : PubMed/NCBI

Schnegg CI, Kooshki M, Hsu FC, Sui G and Robbins ME: PPARdelta prevents radiation-induced proinflammatory responses in microglia via transrepression of NF-kappaB and inhibition of the PKCalpha/MEK1/2/ERK1/2/AP-1 pathway. Free Radic Biol Med. 52:1734–1743. 2012. View Article : Google Scholar : PubMed/NCBI

Matsushita Y, Ogawa D, Wada J, et al: Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice. Diabetes. 60:960–968. 2011. View Article : Google Scholar

Ye JM, Tid-Ang J, Turner N, et al: PPARdelta agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle. Br J Pharmacol. 163:556–566. 2011. View Article : Google Scholar : PubMed/NCBI

Moore-Carrasco R, Poblete Bustamante M, González Guerra O, et al: Peroxisome proliferator-activated receptors: Targets for the treatment of metabolic illnesses (Review). Mol Med Report. 1:317–324. 2008.PubMed/NCBI

Puigserver P, Wu Z, Park CW, Graves R, Wright M and Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 92:829–839. 1998. View Article : Google Scholar : PubMed/NCBI

Wu Z, Puigserver P, Andersson U, et al: Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 98:115–124. 1999. View Article : Google Scholar : PubMed/NCBI

Canto C and Auwerx J: PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. 20:98–105. 2009. View Article : Google Scholar : PubMed/NCBI

Girnun GD: The diverse role of the PPARgamma coactivator 1 family of transcriptional coactivators in cancer. Semin Cell Dev Biol. 23:381–388. 2012. View Article : Google Scholar : PubMed/NCBI

Buechler C and Schäffler A: Does global gene expression analysis in type 2 diabetes provide an opportunity to identify highly promising drug targets? Endocr Metab Immune Disord Drug Targets. 7:250–258. 2007. View Article : Google Scholar : PubMed/NCBI

Schilling J and Kelly DP: The PGC-1 cascade as a therapeutic target for heart failure. J Mol Cell Cardiol. 51:578–583. 2011. View Article : Google Scholar : PubMed/NCBI

Eisele PS, Salatino S, Sobek J, Hottiger MO and Handschin C: The peroxisome proliferator-activated receptor gamma coactivator 1alpha/beta (PGC-1) coactivators repress the transcriptional activity of NF-kappaB in skeletal muscle cells. J Biol Chem. 288:2246–2260. 2013. View Article : Google Scholar

Wang Y, Xu C, Liang Y and Vanhoutte PM: SIRT1 in metabolic syndrome: where to target matters. Pharmacol Ther. 136:305–318. 2012. View Article : Google Scholar : PubMed/NCBI

Porcu M and Chiarugi A: The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci. 26:94–103. 2005. View Article : Google Scholar : PubMed/NCBI

Canto C and Auwerx J: Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev. 64:166–187. 2012.PubMed/NCBI

Hallows WC, Lee S and Denu JM: Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci USA. 103:10230–10235. 2006. View Article : Google Scholar : PubMed/NCBI

Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM and Puigserver P: Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 434:113–118. 2005. View Article : Google Scholar : PubMed/NCBI